Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine
Processa Pharmaceuticals, Inc. announced that the Company has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group. The Processa NGCs already have clinical evidence to support their safety and efficacy while they target patients who need better treatment options for their cancer in order to improve survival and/or quality of life.
“We are pleased to have now dosed the first patient in our 300 mg dose group. This dose group will provide more information on the drug exposure vs adverse event relationship which is critical to FDA approval given FDA’s Project Optimus Oncology initiative. In addition, the data obtained from this dose group will help us to better understand how PCS6422 alters capecitabine metabolism to form more cancer-killing metabolites and fewer metabolites that only cause dose-limiting side effects,” said Dr. David Young, President and CEO of Processa.
Dr. Young added, “We anticipate completion of enrollment in the Phase 1B trial in mid-2023 and are excited to have high exposure of the cancer-killing metabolites without the hand-foot syndrome or cardiotoxicity side effects that typically occur in 50-70% of the patients presently treated with FDA-approved capecitabine. Further, we expect our discussions on our Phase 2B trial with FDA in mid-April to enhance our collaboration with the FDA on their Project Optimus Oncology initiative for all our NGCs while clearing the way to both finalize our Phase 2B protocol and to initiate the trial in the 2nd half of this year.”
The Company will hold its year-end 2022 earnings call on March 30, 2023.